Table 68: Hughes 2000²²⁷

Table 66. Hughes 2000	
Study	Hughes 2000 ²²⁷
Study type	Non-randomised comparative study.
Number of studies (number of participants)	1 (n=111)
Countries and setting	Conducted in United Kingdom; Setting: Hospice.
Line of therapy	Not applicable.
Duration of study	Until death or cessation of symptoms.
Method of assessment of guideline condition	Unclear method of assessment/diagnosis.
Stratum	Overall.

Care of dying adults in the last days of life Clinical evidence tables

Subgroup analysis within study	Not applicable.
Inclusion criteria	People with advanced terminal cancer judged to be within a few days of death. Participants were unconscious with noisy retained secretions that persisted despite repositioning.
Exclusion criteria	Not stated.
Age, gender and ethnicity	Age - Other: Not stated. Gender (M:F): Not stated. Ethnicity:
Indirectness of population	No indirectness.
Interventions	(n=39) Intervention 1: Anti-muscarinic - Hyoscine hydrobromide. Hyoscine hydrobromide 0.4 mg subcutaneously stat, followed by 0.6 mg stat and 2.4 mg/24 hour by syringe driver. Duration Until death or no longer clinically indicated. Concurrent medication/care: Not stated. (n=39) Intervention 2: Anti-muscarinic - Hyoscine butylbromide. Hyoscine butylbromide 20 mg subcutaneously stat, followed by 20 mg stat and 20 mg/24 hour by syringe driver. Duration Until death or no longer clinically indicated. Concurrent medication/care: Not stated. (n=39) Intervention 3: Anti-muscarinic - Glycopyrronium bromide. Glycopyrronium bromide 0.2 mg subcutaneously stat, followed by 0.4 mg stat and 0.6 mg/24 hour by syringe driver. Duration Until death or no longer clinically indicated. Concurrent medication/care: Not stated.
Funding	Funding not stated.

Clinical evidence tables

Care of dying adults in the last days of life

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: HYOSCINE BUTYLBROMIDE versus HYOSCINE HYDROBROMIDE

Protocol outcome 1: Subjective or objective improvement in respiratory secretions at hours/days

- Actual outcome: Level of change in noise intensity of respiratory secretions: absent, much better, slightly better, same, slightly worse, or much worse at Only specified as at death; Group 1: 24/37, Group 2: 20/37; Risk of bias: Very high; Indirectness of outcome: No indirectness.

Protocol outcome 2: Subjective ratings from informal carers' on distress relating to noisy breathing/respiratory secretions at hours/days

- Actual outcome: Change in relatives' distress: absent, much better, slightly better, same, slightly worse, or much worse at Only specified as at death; Group 1: 24/27, Group 2: 27/29; Risk of bias: Very high; Indirectness of outcome: No indirectness.

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: GLYCOPYRRONIUM BROMIDE versus HYOSCINE HYDROBROMIDE

Clinical evidence tables

Care of dying adults in the last days of life

Protocol outcome 1: Subjective or objective improvement in respiratory secretions at hours/days

- Actual outcome: Level of change in noise intensity of respiratory secretions: absent, much better, slightly better, same, slightly worse, or much worse at Only specified as at death; Group 1: 24/37, Group 2: 20/37; Risk of bias: Very high; Indirectness of outcome: No indirectness.

Protocol outcome 2: Subjective ratings from informal carers' on distress relating to noisy breathing/respiratory secretions at hours/days

- Actual outcome: Change in relatives' distress: absent, much better, slightly better, same, slightly worse, or much worse at Only specified as at death; Group 1: 22/25, Group 2: 27/29; Risk of bias: Very high; Indirectness of outcome: No indirectness.

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: GLYCOPYRRONIUM BROMIDE versus HYOSCINE BUTYLBROMIDE

Protocol outcome 1: Subjective or objective improvement in respiratory secretions at hours/days

- Actual outcome: Level of change in noise intensity of respiratory secretions: absent, much better, slightly better, same, slightly worse, or much worse at Only specified as at death; Group 1: 24/37, Group 2: 24/37; Risk of bias: Very high; Indirectness of outcome: No indirectness.

Protocol outcome 2: Subjective ratings from informal carers' on distress relating to noisy breathing/respiratory secretions at hours/days

- Actual outcome: Change in relatives' distress: absent, much better, slightly better, same, slightly worse, or much worse at Only specified as at death; Group 1: 22/25, Group 2: 27/29; Risk of bias: Very high; Indirectness of outcome: No indirectness.

Protocol outcomes not reported by the study

Quality of life at hours/days; Hospitalisation at hours/days; Subjective ratings from people on distress related to noisy breathing /respiratory secretions at hours/days; Sedation (patient-rated, clinician-rated, carer-rated) at hours/days; Adverse events (particularly paradoxical agitation, failure to expectorate, dry mouth at hours/days; Hydration status at hours/days; Length of survival at hours/days; Length of stay at hours/days.